Gestational diabetes mellitus (GDM) is defined as glucose intolerance that is first recognized during pregnancy. It complicates 6–9% of pregnancies in the United States, making it the most common medical complication of pregnancy encountered in clinical nursing practice. Left unmanaged, GDM carries significant risks for both mother and fetus: macrosomia, shoulder dystocia, neonatal hypoglycemia, and a 50% lifetime risk of the mother developing type 2 diabetes within 10 years. For nursing students, GDM is a high-yield NCLEX topic that spans obstetric nursing, pharmacology, and metabolic nursing — tested across all three exam formats (single answer, SATA, and prioritization). This reference covers the pathophysiology, diagnostic criteria, blood glucose targets, nursing interventions, and fetal-neonatal complications you need to manage GDM safely and pass the NCLEX with confidence.
Quick reference: GDM at a glance
| Parameter | Value / Key fact |
|---|---|
| Definition | Glucose intolerance first identified in pregnancy |
| Incidence | 6–9% of US pregnancies |
| Screening timing | 24–28 weeks gestation (all pregnant patients); earlier if high risk |
| 1-step screening (IADPSG) | Fasting OGTT 75 g — any one value meets diagnosis: fasting ≥92, 1-hr ≥180, 2-hr ≥153 mg/dL |
| 2-step screening (ACOG preferred) | Step 1: 1-hr 50 g GCT ≥130–140 mg/dL triggers Step 2; Step 2: 3-hr 100 g OGTT — 2 abnormal values required |
| Fasting glucose target | <95 mg/dL |
| 1-hour postprandial target | <140 mg/dL |
| 2-hour postprandial target | <120 mg/dL |
| First-line treatment | Medical nutrition therapy (MNT) + physical activity |
| Pharmacologic first choice | Insulin (preferred by ACOG over oral agents) |
| Key neonatal complication | Neonatal hypoglycemia — feed within 30–60 minutes of birth |
| Postpartum risk | 50% risk of type 2 DM within 10 years; OGTT at 6–12 weeks postpartum |
Pathophysiology: insulin resistance in pregnancy
Understanding why GDM develops — rather than memorizing isolated facts — makes the clinical picture coherent.
In a normal second and third trimester, the placenta produces progressively higher levels of counter-regulatory hormones: human placental lactogen (hPL), estrogen, progesterone, and cortisol. These hormones are physiologically insulin-resistant; their role is to ensure a sustained supply of maternal glucose for fetal growth. To compensate, the healthy pancreas significantly upregulates insulin secretion. Most pregnant women maintain euglycemia throughout because their beta-cell reserve is sufficient to meet the increased demand.
In women who develop GDM, beta-cell reserve is inadequate to overcome the degree of insulin resistance imposed by placental hormones. Glucose accumulates in maternal circulation and crosses the placenta freely via facilitated diffusion. The fetus responds to hyperglycemia by secreting its own insulin — fetal hyperinsulinism is the direct mechanism behind most GDM complications. Elevated fetal insulin promotes excessive fat deposition (macrosomia), suppresses fetal lung surfactant production, drives erythropoiesis (leading to polycythemia), and primes the neonate for hypoglycemia after delivery, when the maternal glucose supply abruptly stops but fetal insulin secretion remains high.
The insulin resistance resolves rapidly after placental delivery — typically within hours to days. This explains why most GDM resolves postpartum, but the underlying predisposition to beta-cell insufficiency remains and predicts future type 2 diabetes.
Diagnostic criteria: 1-step vs 2-step screening
Two competing screening strategies are in active clinical use, and both appear on NCLEX. The key distinction is that the 2-step approach (endorsed by ACOG) requires two abnormal values to diagnose GDM, while the 1-step approach (endorsed by IADPSG/ADA) diagnoses GDM on any single abnormal value.
| Approach | Test | Fasting | 1-hour | 2-hour | 3-hour | Diagnosis requires |
|---|---|---|---|---|---|---|
| 1-step (IADPSG/ADA) | 75 g OGTT, fasting | ≥92 mg/dL | ≥180 mg/dL | ≥153 mg/dL | N/A | Any 1 abnormal value |
| 2-step (ACOG preferred) | Step 1: 50 g GCT (non-fasting) | N/A | ≥130–140 mg/dL (cut-off varies by center) | N/A | N/A | Positive screen → proceed to Step 2 |
| Step 2: 100 g OGTT, fasting (Carpenter-Coustan criteria) | ≥95 mg/dL | ≥180 mg/dL | ≥155 mg/dL | ≥140 mg/dL | ≥2 abnormal values | |
| Alternative Step 2 | 100 g OGTT (NDDG criteria) | ≥105 mg/dL | ≥190 mg/dL | ≥165 mg/dL | ≥145 mg/dL | ≥2 abnormal values |
Screening timing: All pregnant patients are screened at 24–28 weeks. Earlier screening (at the first prenatal visit) is warranted for patients with risk factors: BMI ≥25, prior GDM, family history of type 2 diabetes, history of macrosomic infant (>4 kg), polycystic ovary syndrome, or members of high-risk ethnic groups (Hispanic, Black, Native American, Asian, Pacific Islander).
Overt diabetes: If fasting glucose is ≥126 mg/dL or a random glucose is ≥200 mg/dL with symptoms at the first prenatal visit, this is preexisting diabetes (overt diabetes in pregnancy), not GDM — it carries higher risk and requires immediate management.
Nursing assessment: what to monitor
Nursing assessment in GDM is organized around maternal glycemic control and fetal well-being. Both require structured, ongoing surveillance.
Maternal glucose monitoring:
The frequency of self-monitored blood glucose (SMBG) depends on treatment intensity. Patients on diet therapy typically check fasting and 2-hour postprandial values daily. Patients on insulin check fasting, preprandial, and 1- or 2-hour postprandial values — often 4–6 times daily.
Review the glucose log at every prenatal visit. Look for patterns: persistent fasting hyperglycemia suggests hepatic gluconeogenesis overnight (often requires bedtime insulin); isolated postprandial spikes after a specific meal suggest a dietary trigger. Both patterns are NCLEX-testable.
Fetal surveillance:
Fetal surveillance intensity is calibrated to glycemic control. The obstetric nursing reference provides the full framework for antepartum testing, but the GDM-specific expectations are:
- Well-controlled GDM on diet alone with no other risk factors: weekly or biweekly nonstress tests (NST) starting at 32–36 weeks (timing varies by protocol)
- GDM requiring medication: NST twice weekly starting at 32 weeks
- Biophysical profile (BPP) added if NST is non-reactive or there is concern for decreased fetal movement
- Ultrasound for estimated fetal weight (EFW) at 32–36 weeks — detection of macrosomia (>4,000 g) informs delivery planning and shoulder dystocia risk
- Kick counts: mothers should report any perceived decrease in fetal movement immediately
Other assessments:
Blood pressure at every visit — GDM approximately doubles the risk of preeclampsia, and the combination of GDM with hypertension markedly increases perinatal morbidity. The preeclampsia nursing reference covers BP thresholds and assessment in detail.
HbA1c at diagnosis (reflects glycemia over the prior 8–12 weeks) and urine protein (or protein:creatinine ratio) at each visit are standard assessments.
Medical management: treatment targets and pharmacology
First-line: medical nutrition therapy (MNT)
MNT is initiated at diagnosis and remains the foundation of all GDM management. The goals are to achieve euglycemia while meeting the caloric needs of pregnancy and avoiding ketoacidosis. A registered dietitian (RD) should develop the individualized plan.
Key MNT principles the nurse reinforces:
- Distribute carbohydrate across 3 meals and 2–3 snacks to blunt postprandial peaks
- Limit refined carbohydrates; emphasize complex carbohydrates with higher fiber content
- Adequate protein and unsaturated fat to maintain satiety
- Moderate aerobic activity (e.g., 30 minutes of walking after meals) reduces postprandial glucose — physical activity is recommended unless obstetric contraindication exists
Approximately 70–85% of GDM patients achieve glucose control on MNT alone. If targets are not met within 1–2 weeks of MNT (or are clearly unachievable due to the degree of hyperglycemia), pharmacologic therapy is added.
Blood glucose targets:
| Measurement point | ADA target | ACOG target | Clinical note |
|---|---|---|---|
| Fasting | ≤95 mg/dL | ≤95 mg/dL | Reflects overnight hepatic glucose output; persistently elevated fasting values often require insulin |
| 1-hour postprandial | ≤140 mg/dL | ≤140 mg/dL | Measured 1 hour after meal start; more sensitive for detecting postprandial spikes |
| 2-hour postprandial | ≤120 mg/dL | ≤120 mg/dL | Some practices use 2-hour only; both approaches are acceptable |
| Bedtime / pre-snack | 100–140 mg/dL | Not separately specified | Guides bedtime snack and overnight insulin dosing |
Pharmacologic management:
When MNT and exercise fail to achieve targets, pharmacologic therapy is initiated. The nurse plays a central role in patient education for all three agents.
| Agent | Mechanism | Placental crossing | ACOG recommendation | Nursing considerations |
|---|---|---|---|---|
| Insulin (NPH, regular, aspart, lispro) | Directly replaces or supplements endogenous insulin; does not depend on beta-cell function | Does not cross the placenta at therapeutic doses | Preferred first-line pharmacologic agent | Teach injection technique, site rotation, hypoglycemia recognition and treatment; NPH has peak effect 4–10 hours after injection — peak hypoglycemia risk midday or overnight; aspart/lispro given with meals; never skip a meal after rapid-acting insulin |
| Metformin | Reduces hepatic gluconeogenesis; improves peripheral insulin sensitivity | Crosses the placenta freely — fetal exposure confirmed; long-term fetal effects still under study | Acceptable when insulin is refused or unavailable; patients should be counseled that it crosses the placenta | GI side effects (nausea, diarrhea) are common and often improve with food; hold for procedures requiring IV contrast; 30–50% of patients on metformin will need supplemental insulin later in pregnancy; instruct patients that they may still need insulin |
| Glyburide | Sulfonylurea — stimulates pancreatic insulin secretion; requires functional beta-cells | Crosses the placenta — detected in fetal cord blood; associated with neonatal hypoglycemia in some studies | Not preferred by ACOG; use only when insulin and metformin are unavailable or refused; some evidence of higher neonatal hypoglycemia and macrosomia rates vs insulin | Higher hypoglycemia risk than metformin; counsel patients that glyburide crosses the placenta; take with or shortly before a meal; monitor neonatal glucose closely if mother received glyburide |
A critical NCLEX distinction: Insulin does not cross the placenta at therapeutic doses. Metformin crosses freely. Glyburide was previously thought to not cross the placenta but is now known to reach measurable fetal concentrations. Insulin is the preferred pharmacologic agent precisely because it does not expose the fetus directly and is the only agent with decades of safety data in pregnancy.
Nursing interventions
Monitoring protocols:
- Review glucose log at each prenatal visit; document all values and identify patterns
- Assess and document injection sites during each visit — lipohypertrophy from poor site rotation impairs insulin absorption
- At hospital admission for labor or antepartum testing: obtain bedside capillary glucose per protocol; frequency varies by glycemic control (typically every 1–4 hours in active labor)
- During labor: target glucose 80–110 mg/dL (tight intrapartum glycemia reduces neonatal hypoglycemia); insulin drip or subcutaneous protocol per provider order
- GDM patients on diet therapy alone rarely require intrapartum insulin but still need glucose monitoring in labor
- After delivery: discontinue all GDM insulin/metformin; glucose monitoring continues for at least 24 hours; most patients return to euglycemia rapidly
Patient education (prioritized):
- Blood glucose monitoring technique — correct lancing, glucose meter use, documentation of values with time relative to meals
- Dietary guidance reinforcement — carbohydrate distribution, portion sizes, foods that predictably spike glucose; refer back to RD
- Hypoglycemia recognition and treatment — symptoms (diaphoresis, tremor, palpitations, confusion), the 15-15 rule (15 g fast-acting carbohydrate, recheck in 15 minutes), when to call the provider
- Insulin injection technique (if applicable) — injection sites, rotation, storage, disposal, never shaking vials
- Kick counts and when to call — report decreased fetal movement immediately
- Postpartum follow-up — OGTT at 6–12 weeks is not optional; 50% risk of T2DM within 10 years; breastfeeding reduces this risk
- Future pregnancy planning — GDM recurs in 40–70% of subsequent pregnancies; preconception counseling and early screening recommended
Hypoglycemia prevention in the hospitalized patient:
Insulin requirements typically drop significantly — or to zero — once labor begins and again immediately after placental delivery. Nurses must reassess the glucose management plan at each of these transitions and verify provider orders rather than continuing the antepartum insulin schedule. Administering antepartum insulin doses postpartum without reassessment is a patient safety risk.
Fetal and neonatal complications
The consequences of fetal hyperinsulinism extend across multiple organ systems. The nurse caring for the neonate of a GDM mother must anticipate and monitor for the following.
Macrosomia (birth weight >4,000 g or >90th percentile for gestational age)
Fetal hyperinsulinism promotes excessive fat deposition, particularly in the trunk and shoulders. The clinical risk is shoulder dystocia during vaginal delivery — a potentially catastrophic obstetric emergency that can result in brachial plexus injury (Erb’s palsy), hypoxic-ischemic encephalopathy, or fetal death. See the discussion in the context of increased postpartum hemorrhage risk — uterine overdistension from macrosomia increases uterine atony risk postpartum. Risk is significantly higher when birth weight exceeds 4,500 g.
Neonatal hypoglycemia
The most immediate neonatal risk and the most tested NCLEX fact in GDM neonatology. After umbilical cord clamping, the maternal glucose supply stops abruptly, but the neonate’s beta-cells continue secreting insulin at the intrauterine-conditioned rate. The result is hypoglycemia within 30–120 minutes of birth. The NCLEX answer: initiate the first feeding within 30–60 minutes of birth and check neonatal glucose before feeding and at 1–2 hours of age per protocol. Threshold for intervention is typically neonatal glucose <40–47 mg/dL in the first 4 hours of life (neonatal glucose values differ from adult targets — confirm by protocol). IV dextrose is required if feeding fails to correct hypoglycemia.
Respiratory distress syndrome (RDS) / transient tachypnea of the newborn
Fetal insulin suppresses cortisol-driven surfactant production. GDM infants, even those born at term, have a higher rate of respiratory distress than gestational age alone would predict. Neonatal respiratory assessment — respiratory rate, nasal flaring, grunting, retractions, pulse oximetry — is a priority in the first hours of life.
Polycythemia
Chronic relative hypoxia in utero (from increased oxygen consumption by the hypermetabolic fetus) stimulates fetal erythropoiesis, leading to elevated hematocrit. Polycythemia increases blood viscosity and the risk of neonatal hyperbilirubinemia (jaundice) and thrombosis. Monitor neonatal hematocrit and bilirubin levels.
Hyperbilirubinemia (neonatal jaundice)
Related to polycythemia and hemolysis of excess red cells. GDM neonates have higher rates of jaundice requiring phototherapy.
Hypocalcemia and hypomagnesemia
Less commonly tested but clinically significant. Fetal hyperinsulinism alters parathyroid hormone secretion, leading to neonatal hypocalcemia. Tremors and jitteriness in the GDM neonate may reflect hypoglycemia, hypocalcemia, or both.
Maternal complications
Preeclampsia
GDM approximately doubles the risk of preeclampsia, likely through shared mechanisms of insulin resistance, endothelial dysfunction, and oxidative stress. Blood pressure monitoring at every prenatal visit is essential — even in patients whose GDM is well controlled. For full preeclampsia diagnostic criteria and management, see the preeclampsia nursing reference.
Cesarean delivery and operative vaginal delivery
Macrosomia increases the rate of cesarean delivery, failed operative vaginal delivery, and fourth-degree perineal lacerations. Women with GDM and an estimated fetal weight >4,500 g are typically counseled regarding planned cesarean delivery to avoid shoulder dystocia.
Polyhydramnios
Fetal hyperglycemia causes fetal polyuria, leading to excess amniotic fluid (polyhydramnios). This further increases the risk of malpresentation, cord prolapse, and uterine overdistension.
Postpartum type 2 diabetes — the 10-year risk
This is the highest-yield NCLEX fact in the maternal complication section. Women who have GDM carry a lifetime risk of approximately 50% of developing type 2 diabetes, with the majority of cases occurring within 5–10 years of the index pregnancy. The postpartum OGTT (75 g, 2-hour test) at 6–12 weeks is the standard of care. Breastfeeding is strongly encouraged — it improves insulin sensitivity and is associated with a measurable reduction in the postpartum T2DM conversion rate.
Glucose monitoring at every subsequent pregnancy is recommended, along with lifestyle counseling emphasizing weight management and physical activity as primary prevention strategies for T2DM.
Postpartum care
The immediate postpartum period brings several nursing priorities specific to GDM.
Glucose monitoring after delivery:
Most GDM patients return to normal glucose within hours of placental delivery. Discontinue antepartum insulin and oral hypoglycemic agents at delivery. Continue capillary glucose monitoring every 4–6 hours for the first 24 hours postpartum. If glucose remains elevated (>200 mg/dL fasting or >250 mg/dL random), consider evaluation for preexisting type 2 diabetes rather than GDM — a GDM diagnosis is by definition not confirmed as overt diabetes until postpartum testing.
Postpartum OGTT — 6–12 weeks:
The 75 g 2-hour OGTT (not HbA1c alone) is the recommended test. ADA and ACOG both recommend this timing because HbA1c may be falsely low in the first 6–12 weeks postpartum due to physiologic changes in red blood cell turnover. Results are interpreted using standard non-pregnant criteria:
- Normal: fasting <100 mg/dL and 2-hour <140 mg/dL
- Prediabetes: fasting 100–125 mg/dL (IFG) or 2-hour 140–199 mg/dL (IGT)
- Type 2 diabetes: fasting ≥126 mg/dL or 2-hour ≥200 mg/dL
Breastfeeding:
Breastfeeding is recommended and actively encouraged in GDM patients. Benefits include improved neonatal glucose stability (breast milk has a lower glycemic index than formula), reduced maternal postpartum weight retention, and a measurable reduction in the mother’s risk of developing type 2 diabetes. For context on glucose values in this setting, the nursing lab values cheat sheet provides normal reference ranges applicable across clinical settings.
Future pregnancy counseling:
GDM recurs in 40–70% of subsequent pregnancies. First-trimester glucose screening is recommended in all subsequent pregnancies, and preconception counseling should include weight optimization and discussion of T2DM risk. Women with prediabetes on their postpartum OGTT should be referred for diabetes prevention program enrollment.
NCLEX high-yield tips
-
Neonatal hypoglycemia — feed within 30–60 minutes of birth. The most commonly tested GDM neonatal fact. Maternal GDM causes fetal hyperinsulinism; after cord clamping, insulin secretion continues but glucose supply stops. The first feeding must occur within 30–60 minutes. Check neonatal glucose before the first feeding and per protocol — the threshold for treatment is typically <40–47 mg/dL in the first 4 hours. IV dextrose is required if oral feeding fails to correct hypoglycemia.
-
Insulin is the preferred pharmacologic agent — it does not cross the placenta. When NCLEX asks which medication is safest for pharmacologic GDM management, the answer is insulin. It does not cross the placenta at therapeutic doses, has the longest safety record, and is the only option with direct evidence of neonatal safety. Oral agents are alternatives when insulin is unavailable or refused.
-
Glyburide does cross the placenta — and is not ACOG’s first choice. A commonly tested NCLEX misconception: glyburide was originally thought to not cross the placenta. Current evidence confirms measurable fetal exposure. ACOG does not recommend glyburide as a first- or second-line agent due to concerns about neonatal hypoglycemia and macrosomia rates compared with insulin.
-
Postpartum OGTT at 6–12 weeks is mandatory — 50% risk of T2DM within 10 years. The postpartum OGTT is not optional screening. It is the standard of care after GDM. HbA1c alone is insufficient at this time point because postpartum red blood cell physiology can produce falsely normal results. The 10-year T2DM conversion rate of ~50% is among the highest testable statistics in obstetric nursing.
-
Breastfeeding reduces postpartum T2DM risk — always encourage it. Breastfeeding improves postpartum insulin sensitivity and is associated with a reduced rate of conversion from GDM to T2DM. On NCLEX, if a question asks about discharge education for a patient with resolved GDM, breastfeeding support is always a correct answer choice.
-
Macrosomia + shoulder dystocia — know the obstetric emergency response. Macrosomia (>4,000 g) from fetal hyperinsulinism is the leading driver of shoulder dystocia. The nurse’s role is anticipating the risk during delivery and assisting with maneuvers: McRoberts’ positioning (hyperflexion of maternal thighs), suprapubic pressure (not fundal pressure, which worsens impaction), Rubin and Woods maneuvers. Do not apply fundal pressure — this is a NCLEX-tested contraindication.
-
GDM doubles preeclampsia risk — BP monitoring is required throughout. A patient with GDM who presents normotensive still requires blood pressure assessment at every visit. GDM is an independent risk factor for preeclampsia, and the combination of GDM with other risk factors (obesity, chronic hypertension, multifetal gestation) substantially increases overall risk.
-
Postprandial glucose patterns guide insulin adjustments — not fasting values alone. If a NCLEX question presents a GDM patient with persistently elevated 2-hour postprandial values despite a normal fasting glucose, the answer involves adding or adjusting mealtime (rapid-acting) insulin — not adjusting the basal/overnight insulin. Conversely, elevated fasting glucose with normal postprandials suggests overnight hepatic gluconeogenesis, addressed with bedtime NPH insulin or long-acting basal insulin.
-
GDM resolves postpartum but antepartum insulin must be discontinued at delivery. Continuing antepartum insulin doses into the postpartum period without reassessment is a patient safety error. After placental delivery, insulin requirements drop dramatically or disappear entirely. Nurses must verify orders at delivery transition and educate patients to stop home insulin unless ordered otherwise.
Related resources
The pathophysiology of GDM builds directly on the mechanisms of type 2 diabetes — the diabetes mellitus nursing reference covers insulin resistance, HbA1c interpretation, and the pharmacology of oral hypoglycemic agents in detail. For the broader labor and delivery framework in which GDM patients are managed, the obstetric nursing reference is the comprehensive starting point.
GDM significantly increases the risk of preeclampsia, and the two conditions frequently coexist — both require close maternal surveillance and coordinated care planning. Macrosomia — the most common fetal complication of poorly controlled GDM — directly increases the risk of uterine atony and postpartum hemorrhage from uterine overdistension; familiarizing yourself with hemorrhage protocols is part of comprehensive GDM preparation.
Blood glucose interpretation in context benefits from the reference ranges in the nursing lab values cheat sheet, and the metabolic context of insulin resistance, altered potassium handling with insulin therapy, and neonatal electrolyte complications is covered in the electrolyte imbalances nursing reference.
Sources: ACOG Practice Bulletin 190 (2018, reaffirmed 2021): Gestational Diabetes Mellitus; ADA Standards of Medical Care in Diabetes — Diabetes in Pregnancy (2024); IADPSG Consensus Panel, Diabetes Care 2010; Carpenter M, Coustan DR, Am J Obstet Gynecol 1982; StatPearls: Gestational Diabetes; Gabbe’s Obstetrics: Normal and Problem Pregnancies, 8th ed.; Blumer I et al., J Clin Endocrinol Metab 2013.